Enclosed herewith Investor Presentation for Unaudited Financial results for Quarter and Half year ended September 30, 2026.

Date: November 05, 2026 To, To, Listing Department Listing Department National Stock Exchange of India Limited BSE Limited (“BSE”) (“NSE”) Department of Corporate Services Exchange Plaza, C-1 Block G, Bandra Kurla Phiroze Jeejeebhoy Towers, Complex Bandra [E], Mumbai – 400051 Dalal Street, Fort, Mumbai - 400 001 NSE Scrip Symbol: PLATIND BSE Scrip Code: 544134 ISIN: INE0PT501018 ISIN: INE0PT501018 Subject: Announcement under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir / Madam, Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed herewith Investors Presentation for the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026. The above information shall be made available on the website of the Company at www.platinumindustriesltd.com This is for your kind information and record. Thanking You Yours Faithfully, For Platinum Industries Limited Bhagyashree Mallawat Company Secretary and Compliance Officer M. No.: A51488 Enclosed: as above. PLATINUM INDUSTRIES LIMITED CIN: L24299MH2020PLC341637 201, Ackruti Star, Pocket No. 5, Central Road, MIDC, Marol, Andheri East, Mumbai-400069, Maharashtra. Tel.: 022-69983999 / 022-69983900 | E-mail: compliance@platinumindustriesltd.com Accelerating Sustainable Growth Investor Presentation Q2 & H1FY27 empowering progress: PlatinumIndustriesLimited www.platinumindustriesltd.com Innovation,Sustainability, andGlobalExpansion Disclaimer This presentation and the following discussion may contain “forward looking statements” by “Platinum Industries Limited” that are not historical in nature. Such forward-looking statements are subject to certain risks and uncertainties such as government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. “Platinum Industries Limited” will not be in any way be responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events orcircumstances. detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www Key Highlights –Q2 & H1FY27 Way Forward Table About Us Business Overview of Contents Market & Opportunity Annual Financials ESG Focus detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www Why Platinum Industries? Key Highlights – Q2 & H1FY27 detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www Key Strategic Update Entry Into Health & Functional Finished Product Exclusive India Partnership with CAREGEN, Korea for “Korglutide” RivaduLifesciences Agreement relates to Agreement executed Provides exclusive Private Limited,a Wholly CAREGEN’s health on 28 September 2026 rights for India Owned subsidiary of functional food finished Platinum Industries, has products marketed under entered into an Exclusive the brand “Korglutide” Sale/Purchase Agreement for India with CAREGEN Co., Ltd., Korea Exclusive India rights with a Korean partner, coupled with potential for local manufacturing, provides Platinum Industries an opportunity to establish a new health and functional finished product and diversify beyond its existing core businesses. detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www Key Business Highlights EGYPT PLANT PALGHAR PLANT (INDIA) On track to commission our state-of-the-art manufacturing facility in Egypt, Capacity Expansion: marking a significant milestone in our global growth strategy. Partial Commercial operations of CPVC at our new Palghar, Maharashtra facility have successfully commenced from 08thAugust 2025. Remaining Commercial Production Start Targeted: The initial capacity of 30,000 MTPA facility has started commercial production on 21stMay 2026. as mentioned in the Prospectus were further increased to 60,000 MTPA. The Key Highlights: partial capacity is expected to commence by 31st December 2026 and the remaining capacity shall be commenced by 31st March 2027. New Capacity: 60,000 TPA (Lead-free / Additives & CPVC etc) Highly De-risked Economics: With low Break-even point, demonstrating 24,000 MTPA 24,000 MTPA 12,000 MTPA strong operating leverage and efficiency. Lead Free PVC CPVC Lubricants/others Game-Changing Location Advantages: Total India Capacity: Scaling towards 85,000+ TPA post full ramp-up • Duty-free access to the USA through Qualified Industrial Zones (QIZ) • Free Trade Agreement (FTA) with key South American markets High Efficiency & Strong Economics: • Cost-competitive supply to two of the world’s largest polymer additives This expansion strengthens our leadership in premium non-lead additives & markets CPVC, improves product mix, and drives strong volume growth & operating leverage in the domestic market & export market The Egypt facility will establish a high-margin global export platform, significantly enhancing our international footprint, margin profile, and will A major step forward in scaling domestic operations and capturing rising be a key driver for scalable, profitable growth in FY28 demand for lead-free solutions & CPVC detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www Key Financial Highlights – Q2 & H1 FY27 enoladnatS detadilosnoC Q2 FY27 H1 FY27 Revenue from Operations EBITDA Revenue from Operations EBITDA In Mn In Mn In Mn In Mn 968.7 1,199.9 141.5 105.4 1,997.6 2,303.6 278.6 233.9 Q2FY26 Q2FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 H1FY26 H1FY27 983.8 1,212.7 2,137.6 2,302.0 287.4 242.7 135.9 108.7 Q2FY26 Q2FY27 Q2FY26 Q2FY27 H1FY26 H1FY27 H1FY26 H1FY27 detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www Income Statement – Q2 & H1FY27 - Standalone Amounts in Mn Q2FY27 Q1FY27 Q2FY26 YoY% QoQ% H1FY27 H1FY26 YoY% Revenue From Operations 1,199.9 1,103.8 968.7 23.9% 8.7% 2,303.6 1,997.6 15.3% Gross Profit 314.8 295.7 287.8 9.4% 6.5% 610.5 574.5 6.3% Gross Margin (%) 26.2% 26.8% 29.7% 26.5% 28.8% EBITDA 105.4 128.5 141.5 -25.5% -18.0% 233.9 278.6 -16.1% EBITDA Margin (%) 8.8% 11.6% 14.6% 10.2% 13.9% Other Income 27.4 22.3 37.4 -26.7% 23.0% 49.7 83.6 -40.5% Depreciation 18.2 14.9 11.9 52.8% 22.2% 33.1 21.9 51.4% PBIT 114.6 135.9 167.0 -31.4% -15.7% 250.5 340.4 -26.4% Interest 7.7 3.9 5.5 39.6% 95.9% 11.6 10.1 15.1% Profit Before Tax 106.9 132.0 161.5 -33.8% -19.0% 238.9 330.3 -27.7% Tax 28.5 36.2 40.1 -28.9% -21.2% 64.7 83.8 -22.8% Profit After Tax 78.4 95.8 121.3 -35.4% -18.2% 174.2 246.5 -29.3% PAT Margin (%) 6.5% 8.7% 12.5% 7.6% 12.3% Earnings Per Share (Rs.) 1.43 1.74 2.21 -35.4% -18.2% 3.17 4.49 -29.3% detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www Income Statement – Q2 & H1FY27 - Consolidated Amounts in Mn Q2FY27 Q1FY27 Q2FY26 YoY% QoQ% H1FY27 H1FY26 YoY% Revenue From Operations 1,212.7 1,089.4 983.8 23.3% 11.3% 2,302.0 2,137.6 7.7% Gross Profit 329.8 308.1 292.6 12.7% 7.0% 637.9 614.8 3.8% Gross Margin (%) 27.2% 28.3% 29.7% 27.7% 28.8% EBITDA 108.3 134.4 135.9 -20.3% -19.5% 242.7 287.4 -15.6% EBITDA Margin (%) 8.9% 12.3% 13.8% 10.5% 13.4% Other Income 27.8 38.2 40.9 -32.1% -27.2% 66.0 87.6 -24.7% Depreciation 21.9 18.2 14.1 55.3% 20.1% 40.1 27.0 48.5% PBIT 114.2 154.4 162.7 -29.8% -26.0% 268.6 348.0 -22.8% Interest 9.0 4.9 9.7 -7.3% 83.6% 13.8 16.9 -17.9% Profit Before Tax 105.2 149.5 153.0 -31.2% -29.6% 254.8 331.2 -23.1% Exceptional Items (5.2) (5.2) PBT (After Exceptional & Other) 105.2 149.5 147.8 -28.8% -29.6% 254.8 326.0 -21.9% Tax 29.3 38.2 38.0 -23.0% -23.5% 67.5 85.4 -21.0% Profit After Tax 76.0 111.3 109.8 -30.8% -31.7% 187.3 240.6 -22.2% PAT Margin (%) 6.3% 10.2% 11.2% 8.1% 11.3% Earnings Per Share (Rs.) 1.40 2.03 2.11 -33.5% -30.7% 3.43 4.43 -22.5% detimiLseirtsudnImunitalP moc.dtlseirtsudnimunitalp.www Balance Sheet - Standalone Particula [Showing first 8,000 characters — download PDF for full document]